Retrieve available abstracts of 294 articles: HTML format
Single Articles
June 2025
BOUAZZI M, Zheng G, Wang J, Baandrup L, et al Use of statins and risk of ovarian cancer: evidence on effect modification by
parity, menopause and endometriosis from nationwide nested case-control studies.
Gynecol Oncol. 2025;198:130-136. PubMedAbstract available
FU Z, Borho L, Taylor SE, Kelemen LE, et al Ovarian cancer risk and survival according to tumor sex hormone receptor
expression: An ovarian Cancer association consortium and ovarian tumor tissue
analysis consortium pooled analysis.
Gynecol Oncol. 2025;198:112-129. PubMedAbstract available
May 2025
KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and
steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
Gynecol Oncol. 2025;198:90-95. PubMedAbstract available
NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al Patients with advanced ovarian cancer and their experiences and perceptions of
sleep disturbance and fatigue across the treatment trajectory: A qualitative
study.
Gynecol Oncol. 2025;198:42-48. PubMedAbstract available
KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
Gynecol Oncol. 2025;197:121-128. PubMedAbstract available
EVANS E, Dholakia J, Abraham J, Hinton A, et al Whole-exome sequencing provides assessment of homologous recombination deficiency
for identification of PARPi-responsive ovarian tumors.
Gynecol Oncol. 2025;197:139-145. PubMedAbstract available
KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al Impact of mismatch repair (MMR) status on recurrence in high intermediate risk
endometrial cancer.
Gynecol Oncol. 2025;197:116-120. PubMedAbstract available
SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al Association of endometrial cancer epigenetic mismatch repair deficiency with
clinicopathologic factors and survival in a large, diverse community-based
cohort.
Gynecol Oncol. 2025;197:102-109. PubMedAbstract available
THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of
IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients
newly-diagnosed with advanced epithelial ovarian cancer.
Gynecol Oncol. 2025 May 2:S0090-8258(25)00797. PubMedAbstract available
April 2025
LOUKOVAARA M, Pasanen A, Butzow R Molecular subgroup-specific prognostic value of semiquantitative lymphovascular
space invasion in early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2025;197:96-101. PubMedAbstract available
POVEDA A, Lheureux S, Colombo N, Cibula D, et al Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed
ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall
survival results from the OPINION trial.
Gynecol Oncol. 2025;197:74-82. PubMedAbstract available
YOU B, Anderson C, Cecere SC, Carrot A, et al Impact of adding the immune checkpoint inhibitor atezolizumab to first-line
chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A
retrospective analysis from the IMagyn050 trial.
Gynecol Oncol. 2025;197:66-73. PubMedAbstract available
XIE J, Maguire FB, Hofer BM, Cooley JJP, et al Disparities in hysterectomy-corrected endometrial cancer incidence trends by
histologic subtype among racial/ethnic groups in California, 2012-2019.
Gynecol Oncol. 2025;197:34-42. PubMedAbstract available
WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al Disparities in facility-level adoption of minimally invasive interval debulking
surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;197:11-18. PubMedAbstract available
ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al The prognostic potential of molecular subtypes including estrogen receptor status
in endometrioid ovarian cancer.
Gynecol Oncol. 2025;196:137-145. PubMedAbstract available
RAIMONDO D, Raffone A, Maletta M, Restaino S, et al Hysterectomy or not for borderline ovarian tumor in menopause?
Gynecol Oncol. 2025;196:152-159. PubMedAbstract available
METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A
comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal
POLE-mutated recurrence.
Gynecol Oncol. 2025;196:129-136. PubMedAbstract available
HABLASE R, Steinke J, Aslam A, Jose R, et al Anastomotic leakage in colorectal and ovarian cancer resections: A comparative
cohort study.
Gynecol Oncol. 2025;196:121-128. PubMedAbstract available
GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or
2, =50 % invasive endometrial cancer: Candidates for adjuvant therapy.
Gynecol Oncol. 2025;196:113-120. PubMedAbstract available
KAHN RM, Murphy K, Patel T, Yeoshoua E, et al Three-dimensional volumetric rendering on augmented reality headsets for ovarian
cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team
Ovary study.
Gynecol Oncol. 2025;196:107-112. PubMedAbstract available
VARGIU V, Santullo F, Scambia G, Naldini A, et al STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a
restrictive policy on the use of protective stoMAs.
Gynecol Oncol. 2025;196:92-98. PubMedAbstract available
HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al MUTYH: Possibly another important gene in ovarian cancer?
Gynecol Oncol. 2025;196:59-61. PubMed
BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al Signal transduction pathway activity in adult-type granulosa cell tumor samples.
Gynecol Oncol. 2025;195:6-11. PubMedAbstract available
March 2025
MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and
long-term safety.
Gynecol Oncol. 2025;195:192-199. PubMedAbstract available
ETHIER JL, Shephard C, Granados DP, Dutta N, et al Comparative efficacy and safety of low-dose versus high-dose bevacizumab in
ovarian cancer: An indirect treatment comparison.
Gynecol Oncol. 2025;196:1-9. PubMedAbstract available
JOHANNET P, Flint M, Chui MH, Konner J, et al Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1
antibody-drug conjugate.
Gynecol Oncol. 2025;195:173-179. PubMedAbstract available
LI Y, Wu M, Liu Q, Huang C, et al Development and validation of an ovarian cancer risk assessment tool for
first-degree relatives of patients in the Chinese population.
Gynecol Oncol. 2025;195:165-172. PubMedAbstract available
SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al Anaplastic carcinoma of the ovary: A single-institution experience and molecular
analysis.
Gynecol Oncol. 2025;195:144-148. PubMedAbstract available
CARUSO G, Kumar A, Langstraat CL, McGree ME, et al Racial/ethnic, socioeconomic, and healthcare access disparities in achieving
textbook oncologic outcome in advanced ovarian cancer.
Gynecol Oncol. 2025;195:106-114. PubMedAbstract available
SALINARO J, Singh K, Sands N, Gill V, et al Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
Gynecol Oncol. 2025;195:115-121. PubMedAbstract available
LI X, Wang Z, Man X, Dai X, et al Research advances CRISPR gene editing technology generated models in the study of
epithelial ovarian carcinoma.
Gynecol Oncol. 2025;195:34-44. PubMedAbstract available
HICKS A, Borho L, Elishaev E, Berger J, et al All-cause mortality and neighborhood social vulnerability among women with
ovarian cancer.
Gynecol Oncol. 2025;195:26-33. PubMedAbstract available
MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al Integrating clinical-molecular data to predict PARP inhibitors efficacy in
advanced ovarian cancer patients after interval cytoreductive surgery.
Gynecol Oncol. 2025;195:16-25. PubMedAbstract available
HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al An open-label randomized active-controlled phase II clinical study to assess the
efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients
with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Gynecol Oncol. 2025;194:145-152. PubMedAbstract available
LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell
tumor.
Gynecol Oncol. 2025;194:125-130. PubMedAbstract available
ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and
predictive value in High-Grade Serous Carcinoma (HGSC).
Gynecol Oncol. 2025;194:1-10. PubMedAbstract available
February 2025
ASARE A, Previs RA, Spinosa D, Fellman B, et al Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in
patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Gynecol Oncol. 2025;194:112-118. PubMedAbstract available
ALVERO AB, Wu S, Farrell A, Kim S, et al Exploring the differences between BRCA mutated and HRwild-type high grade serous
ovarian cancer: A multiomic analysis.
Gynecol Oncol. 2025;194:71-79. PubMedAbstract available
SUN H, Huo X, Bi X, Cao D, et al Exosome transmit the ability of migration and invasion in heterogeneous ovarian
cancer cells by regulating autophagy via targeting hsa-miR-328.
Gynecol Oncol. 2025;194:60-70. PubMedAbstract available
MATSUO K, Agarwal J, Chen L, Furey KB, et al Histology-specific prognostic significance of isolated tumor cells,
micrometastases, and macrometastases in endometrial cancer.
Gynecol Oncol. 2025;194:51-59. PubMedAbstract available
GAILLARD S, Verma N, Berg M, Harrison J, et al A clinical study of tremelimumab, alone or in combination with olaparib, for
recurrent epithelial ovarian cancer.
Gynecol Oncol. 2025;194:41-47. PubMedAbstract available
CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al HER2 expression in a molecularly defined cohort of endometrial cancer patients:
The SPECTRUM study.
Gynecol Oncol. 2025;194:33-40. PubMedAbstract available
KIM J, Park SY, Kim JH, Lee SW, et al Real-world efficacy and toxicity of olaparib maintenance therapy in Korean
ovarian cancer patients with an exploratory analysis of BRCA mutations.
Gynecol Oncol. 2025;194:25-32. PubMedAbstract available
ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al Metformin for patients with advanced stage ovarian cancer: A randomized phase II
placebo-controlled trial.
Gynecol Oncol. 2025;194:18-24. PubMedAbstract available
VALENZA C, Mongillo M, Visconti MV, Katrini J, et al Rechallenge with platinum-based chemotherapy in patients with platinum-resistant
ovarian carcinoma: A cohort study.
Gynecol Oncol. 2025;194:11-17. PubMedAbstract available
CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in
patients with high-grade serous ovarian cancer with high CD8 T-cell density.
Gynecol Oncol. 2025;193:148-155. PubMedAbstract available
January 2025
MAKI PM, Rubin LH, Krejany EO, Brand A, et al What happens after menopause? (WHAM): A prospective controlled study of cognition
24 months after premenopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2025;193:141-147. PubMedAbstract available
TOBONI MD, Dinkins K, Wu S, Mattox T, et al Not all uterine carcinosarcomas are created equal: Survival outcomes according to
molecular characterization of uterine carcinosarcoma.
Gynecol Oncol. 2025;193:89-97. PubMedAbstract available
WANG H, Zhu J, Zou D, Rao Q, et al Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol. 2025;193:58-64. PubMedAbstract available
RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al Prognostic significance of serum complement activation, neutrophil extracellular
traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2025;193:49-57. PubMedAbstract available
BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol. 2025;193:30-40. PubMedAbstract available
MARINO G, Marchetta L, Negri S, Testa F, et al Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor -
a retrospective single centre analysis.
Gynecol Oncol. 2025;192:89-93. PubMedAbstract available
December 2024
KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy
in patients with ovarian cancer: A scoping review.
Gynecol Oncol. 2024;192:155-162. PubMedAbstract available
AZAIS H, Brochard C, Taly V, Benoit L, et al Prognostic value of circulating tumor DNA at diagnosis and its early decrease
after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial
ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol. 2024;192:145-154. PubMedAbstract available
MIRZA MR, Bjorge L, Marme F, Christensen RD, et al Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent
endometrial cancer: Double-blind placebo-controlled randomized phase II
ENGOT-EN3/PALEO trial.
Gynecol Oncol. 2024;192:128-136. PubMedAbstract available
GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al Association between genomic instability score and progression-free/overall
survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Gynecol Oncol. 2024;192:120-127. PubMedAbstract available
PREVIS RA, Strickland KC, Wallen Z, Ko H, et al Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary
peritoneal cancers.
Gynecol Oncol. 2024;192:102-110. PubMedAbstract available
November 2024
SHU T, Liang Y, Zhang S, Sun T, et al The prognostic value of tumor-informed minimal residual disease detection using
circulating tumor DNA in first-line treatment of ovarian cancer.
Gynecol Oncol. 2024;192:94-101. PubMedAbstract available
BORHO L, Elishaev E, Bao R, O'Brien E, et al Association of neighborhood social vulnerability with ovarian cancer survival.
Gynecol Oncol. 2024;192:32-39. PubMedAbstract available
SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al Repair Assisted Damage Detection (RADD) as a predictive biomarker for
immunotherapy response in ovarian cancer.
Gynecol Oncol. 2024;192:65-72. PubMedAbstract available
FRANCIS KE, Simon S, Gebski V, Joly F, et al Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of
olaparib in recurrent ovarian cancer.
Gynecol Oncol. 2024;192:50-55. PubMedAbstract available
MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial
cancers of no specific molecular profile.
Gynecol Oncol. 2024;192:8-14. PubMedAbstract available
HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al What happens after menopause? (WHAM): Impact of risk-reducing
salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
Gynecol Oncol. 2024;192:1-7. PubMedAbstract available
LEE AW, Poynor V, Siddiqui S Disparities in ovarian cancer survival among ethnic Asian American populations,
2006-2020.
Gynecol Oncol. 2024;191:292-298. PubMedAbstract available
WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al Serum miRNA improves the accuracy of a multivariate index assay for triage of an
adnexal mass.
Gynecol Oncol. 2024;190:124-130. PubMedAbstract available
METCALF CA, Page CE, Stocker BOS, Johnson RL, et al Treating new-onset cognitive complaints after risk-reducing
salpingo-oophorectomy: A randomized controlled crossover trial of
lisdexamfetamine.
Gynecol Oncol. 2024;190:62-69. PubMedAbstract available
TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1
germline mutations.
Gynecol Oncol. 2024;190:18-27. PubMedAbstract available
October 2024
MOORE KN, Lorusso D, Oaknin A, Oza A, et al Safety and tolerability of mirvetuximab soravtansine monotherapy for folate
receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Gynecol Oncol. 2024;191:249-258. PubMedAbstract available
GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al Phase II clinical trial assessing the efficacy of enzalutamide in advanced
non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
Gynecol Oncol. 2024;191:233-239. PubMedAbstract available
HICKEY M, Trainer AH, Krejany EO, Brand A, et al What happens after menopause? (WHAM): A prospective controlled study of vasomotor
symptoms and menopause-related quality of life 24 months after premenopausal
risk-reducing salpingo-oophorectomy (RRSO).
Gynecol Oncol. 2024;191:201-211. PubMedAbstract available
YONEMORI K, Boni V, Min KG, Meniawy TM, et al Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and
combined with abemaciclib, in recurrent/advanced ER-positive endometrioid
endometrial cancer: Results from the phase 1a/1b EMBER study.
Gynecol Oncol. 2024;191:172-181. PubMedAbstract available
OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian
cancer, translational analyses of the Phase 3 iPocc trial.
Gynecol Oncol. 2024;191:124-131. PubMedAbstract available
PINTO P, Moro F, Alcazar JL, Alessi S, et al Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal
Cancer Index - A prospective multicentric study using imaging (ISAAC study).
Gynecol Oncol. 2024;191:132-142. PubMedAbstract available
CARUSO G, Langstraat CL, Kumar A, McGree ME, et al Textbook oncologic outcome is an easy-to-use composite quality measure that is
strongly associated with survival in advanced-stage ovarian cancer.
Gynecol Oncol. 2024;191:86-94. PubMedAbstract available
RUSHTON T, Krause HB, Samec T, Elliott A, et al Characterizing the genomic landscape through the lens of FOLR1 status in low and
high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:80-85. PubMedAbstract available
LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent
refractory ovarian cancer.
Gynecol Oncol. 2024;191:74-79. PubMedAbstract available
September 2024
WAN S, Gao Y, Wu S, Wang H, et al Somatic mutation of targeted sequencing identifies risk stratification in
advanced ovarian clear cell carcinoma.
Gynecol Oncol. 2024;191:56-66. PubMedAbstract available
LI X, Argenta PA, Brown K, Honeyfield K, et al Associations of cytomegalovirus infection with cancer-related cognitive
impairment and peripheral neuropathy in ovarian cancer survivors.
Gynecol Oncol. 2024;191:25-30. PubMedAbstract available
JANG EB, Lee AJ, So KA, Lee SJ, et al Risk factors for the recurrence in patients with early endometrioid endometrial
cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol. 2024;191:19-24. PubMedAbstract available
NIEF CA, Long SE, McCleary TL, Kidd E, et al Diabetes mellitus complications associated with recurrence of stage I
endometrioid endometrial cancer: A single-center retrospective study.
Gynecol Oncol. 2024;190:298-306. PubMedAbstract available
BROWN J, Miller A, Holman LL, Backes F, et al Results of a randomized phase II trial of paclitaxel and carboplatin versus
bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive
stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Gynecol Oncol. 2024;190:283-290. PubMedAbstract available
ADJEI NN, Haas A, Zhao H, Primm KM, et al Real-world trends in the use of maintenance therapy in ovarian cancer across the
United States from 2017 to 2021.
Gynecol Oncol. 2024;190:255-261. PubMedAbstract available
MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al Physical and psychological distress amongst patients undergoing neoadjuvant
chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2024;190:230-235. PubMedAbstract available
August 2024
MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al Frailty in patients with ovarian cancer and the role of healthcare access, race,
and ethnicity.
Gynecol Oncol. 2024;190:146-152. PubMedAbstract available
QI C, Lyu M, Yao Z, Zhang F, et al SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition
under hypoxic conditions through the TGF-beta/Smad pathway.
Gynecol Oncol. 2024;190:167-178. PubMedAbstract available
SKOF E, Stegel V, Dragos VS, Blatnik A, et al Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib
maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A
single center report.
Gynecol Oncol. 2024;190:104-112. PubMedAbstract available
BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al The association of maintenance hormone therapy with overall survival in
advanced-stage low-grade serous ovarian carcinoma: A risk-set matched
retrospective study.
Gynecol Oncol. 2024;190:119-123. PubMedAbstract available
YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al Investigating the timing and site of recurrence for ovarian clear cell carcinoma:
Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
Gynecol Oncol. 2024;190:113-118. PubMedAbstract available
LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al Quality of life and survivorship in patients with low-grade ovarian cancer.
Gynecol Oncol. 2024;190:96-103. PubMedAbstract available
ROSS TL, Na R, Au-Yeung G, DeFazio A, et al Are exercise and sitting time during chemotherapy for ovarian cancer associated
with treatment-related side-effects, chemotherapy completion and survival?
Gynecol Oncol. 2024;190:53-61. PubMedAbstract available
YOKOI A, Machida H, Shimada M, Mastuo K, et al Efficacy and safety of minimally invasive surgery versus open laparotomy for
epithelial ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;190:42-52. PubMedAbstract available
CUN HT, Bernard L, Lande KT, Lawson BC, et al Comprehensive molecular characterization of early stage grade 3 endometrioid
endometrial adenocarcinoma.
Gynecol Oncol. 2024;189:138-145. PubMedAbstract available
VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al Quality of life among borderline ovarian tumor survivors: A comparison with
survivors of early-stage ovarian cancer and a cancer-free population: A
cross-sectional population-based PROFILES study.
Gynecol Oncol. 2024;189:111-118. PubMedAbstract available
STROOT IAS, Bart J, Hollema H, Jalving M, et al Long-term outcome of high-grade serous carcinoma established in risk-reducing
salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic
variant carriers.
Gynecol Oncol. 2024;187:198-203. PubMedAbstract available
VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal
relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2
mutation carriers several years after risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2024;187:113-119. PubMedAbstract available
July 2024
JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al Health-related quality of life, sexual function, psychological health,
reproductive concerns and fertility outcome in young women treated with
fertility-sparing surgery for ovarian tumors - A prospective longitudinal
multicentre study.
Gynecol Oncol. 2024;189:101-108. PubMedAbstract available
GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al Vaccination with folate receptor-alpha peptides in patients with ovarian cancer
following response to platinum-based therapy: A randomized, multicenter clinical
trial.
Gynecol Oncol. 2024;189:90-97. PubMedAbstract available
FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al ChatGPT compared to national guidelines for management of ovarian cancer: Did
ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary
study.
Gynecol Oncol. 2024;189:75-79. PubMedAbstract available
KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al Patterns of initial ovarian cancer recurrence on niraparib maintenance
monotherapy in patients with no baseline evidence of disease after first-line
chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol. 2024;189:68-74. PubMedAbstract available
POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al Occult residual ovarian tissue at the time of minimally invasive risk reducing
surgery in women with BRCA mutations.
Gynecol Oncol. 2024;189:37-40. PubMedAbstract available
ANDRES S, Finch L, Iasonos A, Zhou Q, et al Basket study of oral progesterone antagonist onapristone extended release in
progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian
cancer, or endometrioid endometrial cancer.
Gynecol Oncol. 2024;189:30-36. PubMedAbstract available
MAHONEY DE, Mukherjee R, Thompson J Elucidating the influences of social determinants of health on perceived overall
health among African American/Black and Hispanic ovarian cancer survivors using
the NIH All of Us Research Program.
Gynecol Oncol. 2024;189:24-29. PubMedAbstract available
MCNAMARA B, Greenman M, Bellone S, Santin LA, et al Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed
antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in
ovarian carcinoma.
Gynecol Oncol. 2024;189:16-23. PubMedAbstract available
RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al The karyometric signature is altered in fallopian tubes with serous tubal
intraepithelial carcinoma.
Gynecol Oncol. 2024;186:110-116. PubMedAbstract available
June 2024
FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
Gynecol Oncol. 2024;188:97-102. PubMedAbstract available
MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the
anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
Gynecol Oncol. 2024;188:103-110. PubMedAbstract available
MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring
new therapeutic possibilities.
Gynecol Oncol. 2024;188:52-57. PubMedAbstract available
KOH B, Ryu JY, Noh JJ, Hwang JR, et al Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant
ovarian cancer.
Gynecol Oncol. 2024;188:60-70. PubMedAbstract available
EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al Corrigendum to "Incidence, treatment, and survival trends in older versus younger
women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish
study" [Gynecologic Oncology 164/1(2022) 120-128].
Gynecol Oncol. 2024;188:58-59. PubMed
BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al The prognostic impact of substantial lymphovascular space invasion in women with
node negative FIGO stage I uterine carcinoma.
Gynecol Oncol. 2024;188:44-51. PubMedAbstract available
BORHO L, Bao R, Elishaev E, Dinkins KD, et al Association of allostatic load with overall survival in epithelial ovarian
cancer.
Gynecol Oncol. 2024;186:204-210. PubMedAbstract available
VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al Efficacy and safety of niraparib in patients aged 65 years and older with
advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;187:128-138. PubMedAbstract available
O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al Unmet financial needs among patients crowdfunding to support gynecologic cancer
care.
Gynecol Oncol. 2024;186:199-203. PubMedAbstract available
AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al Comprehensive next-generation sequencing identifies novel putative pathogenic or
likely pathogenic germline variants in patients with concurrent tubo-ovarian and
endometrial serous and endometrioid carcinomas or precursors.
Gynecol Oncol. 2024;187:241-248. PubMedAbstract available
SCALISE CB, Kincaid K, Thigpen H, Moore J, et al A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and
WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol. 2024;185:83-94. PubMedAbstract available
May 2024
FRANCO S, Godley LA Myeloid neoplasms in individuals with breast and ovarian cancer and the
association with deleterious germline variants.
Gynecol Oncol. 2024;187:235-240. PubMedAbstract available
LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al Preferences and considerations for interval cytoreductive surgery in advanced
ovarian cancer: The patient's perspective.
Gynecol Oncol. 2024;187:227-234. PubMedAbstract available
PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al Homologous recombination deficiency should be tested for in patients with
advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol. 2024;187:221-226. PubMedAbstract available
YUAN G, Zhang K, Zheng H, Wu Y, et al Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian
tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
Gynecol Oncol. 2024;187:212-220. PubMedAbstract available
CARBALLO EV, Kim KH, Penn CA Trends in estimated PARP inhibitor eligibility and benefit among US epithelial
ovarian cancer patients.
Gynecol Oncol. 2024;187:204-211. PubMedAbstract available
LARAJA A, Connor Y, Poulson MR The effect of urban racial residential segregation on ovarian cancer diagnosis,
treatment, and survival.
Gynecol Oncol. 2024;187:163-169. PubMedAbstract available
MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al Clinical characteristics and survival outcome of early-stage, high-grade, serous
tubo-ovarian carcinoma according to BRCA mutational status.
Gynecol Oncol. 2024;187:170-177. PubMedAbstract available
ZENATRI M, Perennec T, Michon C, Gernier F, et al Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral
neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire
study.
Gynecol Oncol. 2024;187:139-144. PubMedAbstract available
LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al A phase 2 trial exploring the significance of homologous recombination status in
patients with platinum sensitive or platinum resistant relapsed ovarian cancer
receiving combination cediranib and olaparib.
Gynecol Oncol. 2024;187:105-112. PubMedAbstract available
ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al Feasibility and operative outcomes of surgery in the liver area in advanced
ovarian cancer.
Gynecol Oncol. 2024;187:98-104. PubMedAbstract available
FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al Trends in specific procedures performed at the time of cytoreduction for ovarian
cancer: Is interval debulking surgery truly less radical? A Memorial Sloan
Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;187:80-84. PubMedAbstract available
PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al Correlating the KELIM (CA125 elimination rate constant K) score and the
chemo-response score as predictors of chemosensitivity in patients with advanced
ovarian carcinoma.
Gynecol Oncol. 2024;187:92-97. PubMedAbstract available
LIANG S, Ge H, Zhou S, Tang J, et al Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular
characteristics of persistent and recurrent OYST.
Gynecol Oncol. 2024;187:64-73. PubMedAbstract available
GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al Lenvatinib plus pembrolizumab for patients with previously treated advanced
ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol. 2024;186:182-190. PubMedAbstract available
PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al Neural network-derived multivariate index assay demonstrates effective clinical
performance in longitudinal monitoring of ovarian cancer risk.
Gynecol Oncol. 2024;187:21-29. PubMedAbstract available
MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al Efficacy of stereotactic body radiotherapy and response prediction using
artificial intelligence in oligometastatic gynaecologic cancer.
Gynecol Oncol. 2024;184:16-23. PubMedAbstract available
April 2024
HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al Walking the tightrope: Fertility preservation among hereditary breast and ovarian
Cancer syndrome Previvors.
Gynecol Oncol. 2024;186:176-181. PubMedAbstract available
SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al "Having cancer is very expensive": A qualitative study of patients with ovarian
cancer and PARP inhibitor treatment.
Gynecol Oncol. 2024;186:170-175. PubMedAbstract available
CHALIF J, Chambers LM, Yao M, Kuznicki M, et al Extended-duration antibiotics are not associated with a reduction in surgical
site infection in patients with ovarian cancer undergoing cytoreductive surgery
with large bowel resection.
Gynecol Oncol. 2024;186:161-169. PubMedAbstract available
ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al Effect of surgical volume on short-term outcomes of cytoreductive surgery for
advanced-stage ovarian cancer: A population-based study from the Dutch
Gynecological Oncology Audit.
Gynecol Oncol. 2024;186:144-153. PubMedAbstract available
NELSON AT, Harris AK, Watson D, Kamihara J, et al Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International
Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor
Registries.
Gynecol Oncol. 2024;186:117-125. PubMedAbstract available
EHMANN S, Lam C, Zhou Q, Iasonos A, et al Secondary cytoreductive surgery and oncologic outcomes in the era of targeted
maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;186:104-109. PubMedAbstract available
ESPINOSA I, D'Angelo E, Prat J Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical
reappraisal with comments on FIGO 2023 staging.
Gynecol Oncol. 2024;186:94-103. PubMedAbstract available
GITTO SB, Ihewulezi CJN, Powell DJ Jr Adoptive T cell therapy for ovarian cancer.
Gynecol Oncol. 2024;186:77-84. PubMedAbstract available
DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al Has time to chemotherapy from primary debulking surgery in advanced ovarian
cancer an impact on survival? - A population-based nationwide SweGCG study.
Gynecol Oncol. 2024;186:69-76. PubMedAbstract available
GIEN LT, Enserro DM, Block MS, Waggoner S, et al Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma
of the ovary: An NRG oncology study GY016.
Gynecol Oncol. 2024;186:61-68. PubMedAbstract available
SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al Predictors of germline genetic testing referral and completion in ovarian cancer
patients at a Comprehensive Cancer Center.
Gynecol Oncol. 2024;186:53-60. PubMedAbstract available
KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al Disease progression, survival, and molecular disparities in Black and White
patients with endometrioid endometrial carcinoma in real-world registries and
GOG/NRG oncology randomized phase III clinical trials.
Gynecol Oncol. 2024;183:103-114. PubMedAbstract available
HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al High throughput screening identifies dasatinib as synergistic with trametinib in
low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:42-52. PubMedAbstract available
March 2024
MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al TP53 mutations and the association with platinum resistance in high grade serous
ovarian carcinoma.
Gynecol Oncol. 2024;186:26-34. PubMedAbstract available
HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al Comparing survival of older ovarian cancer patients treated with neoadjuvant
chemotherapy versus primary cytoreductive surgery: Reducing bias through machine
learning.
Gynecol Oncol. 2024;186:9-16. PubMedAbstract available
PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of
clinical activity.
Gynecol Oncol. 2024;183:61-67. PubMedAbstract available
HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al Demographic, clinical, and sociocognitive determinants related to physical
activity and dietary intake in patients with ovarian cancer: A cross-sectional
study.
Gynecol Oncol. 2024;183:39-46. PubMedAbstract available
LEVINE BJ Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer
diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155. PubMed
CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al Fertility potential and safety assessment of residual ovarian cortex in young
women diagnosed with epithelial borderline and early-stage malignant ovarian
tumors.
Gynecol Oncol. 2024;183:15-24. PubMedAbstract available
BYRNE M, Sia TY, Fong C, Khurram A, et al Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic
testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144. PubMedAbstract available
RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha
(FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and
bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193. PubMedAbstract available
NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA Real world challenges and disparities in the systemic treatment of ovarian
cancer.
Gynecol Oncol. 2024;185:180-185. PubMedAbstract available
CHEN W, Xie J, Gao C, Zhang C, et al Hypertension associated with niraparib in cancer patients: A pharmacovigilance
analysis based on the FAERS database and meta-analysis of randomized controlled
trials.
Gynecol Oncol. 2024;182:108-114. PubMedAbstract available
February 2024
COSTALES AB, Crane EK, Chambers L, Yao M, et al Laparoscopic predictability of minimally invasive interval debulking in advanced
ovarian cancer: The MIID-SOC trial.
Gynecol Oncol. 2024;185:143-147. PubMedAbstract available
SALMAN L, Covens A, Vicus D, Podolsky S, et al The role of surgeon specialty in management and survival of malignant ovarian
germ cell tumors: A population-based study.
Gynecol Oncol. 2024;185:138-142. PubMedAbstract available
RONCOLATO F, King MT, O'Connell RL, Lee YC, et al Hidden in plain sight - Survival consequences of baseline symptom burden in women
with recurrent ovarian cancer.
Gynecol Oncol. 2024;185:128-137. PubMedAbstract available
PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al Incidence and risk factors of venous and arterial thromboembolic events among
patients with ovarian cancer- data from a large Canadian database.
Gynecol Oncol. 2024;185:116-120. PubMedAbstract available
KRISTENSEN AK, Frandsen CLB, Nohr B, Viuff JH, et al Risk of borderline ovarian tumors after fertility treatment - Results from a
Danish cohort of infertile women.
Gynecol Oncol. 2024;185:108-115. PubMedAbstract available
SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al Determination of quality of life-related health utilities for surgical
complications in ovarian cancer.
Gynecol Oncol. 2024;185:101-107. PubMedAbstract available
DISIPIO T, Hartel G, Butow P, Webb PM, et al Impact of disease recurrence on the supportive care needs of patients with
ovarian cancer and their caregivers.
Gynecol Oncol. 2024;185:33-41. PubMedAbstract available
ABADA E, Kim S, Jang H, Kheil M, et al Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade
endometrial endometrioid carcinoma: Clinicopathologic characteristics and future
directions.
Gynecol Oncol. 2024;185:25-32. PubMedAbstract available
CHANG C, Cheng YY, Kamlapurkar S, White S, et al GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of
GDF15.
Gynecol Oncol. 2024;185:8-16. PubMedAbstract available
MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK
inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043. PubMedAbstract available
WESSMAN S, Nister M, Kokaraki G, Pal N, et al A comprehensive population-based study of malignant ovarian tumors, including
histologic and immunohistochemical review, in children and adolescents 0-19 years
old in Sweden between 1970 and 2014.
Gynecol Oncol. 2024;184:206-213. PubMedAbstract available
SOMASEGAR S, Reddy RA, Chow S, Dorigo O, et al Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence,
mortality, and survival: A 15-year population-based analysis.
Gynecol Oncol. 2024;184:190-197. PubMedAbstract available
POTHURI B, Han S, Chase DM, Heitz F, et al Health-related quality of life in patients with newly diagnosed advanced ovarian
cancer treated with niraparib vs placebo: Results from the phase 3 randomized
PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;184:168-177. PubMedAbstract available
SMITH AJB, Gleason EG, Andriani L, Heintz J, et al Variation in telemedicine usage in gynecologic cancer: Are we widening or
narrowing disparities?
Gynecol Oncol. 2024;184:160-167. PubMedAbstract available
TELLES R, Zimmerman MB, Thaker PH, Slavich GM, et al Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer
patients.
Gynecol Oncol. 2024;184:139-145. PubMedAbstract available
HARI A, Chang J, Villanueva C, Ziogas A, et al Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
Gynecol Oncol. 2024;184:123-131. PubMedAbstract available
YOON H, Suh DH, Kim K, No JH, et al Evaluation of prognostic potential of beta-catenin and L1CAM expression according to
endometrial cancer risk group.
Gynecol Oncol. 2024;184:132-138. PubMedAbstract available
TAYLOR DD, Gercel-Taylor C, Parker LP Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic
markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
Gynecol Oncol. 2024;181:186. PubMed
VASTA FM, Cormio G, Cassani C, Bergamini A, et al Reproductive outcomes after conservative treatment in early and advanced stage
MOGCTs.
Gynecol Oncol. 2024;181:28-32. PubMedAbstract available
January 2024
SANTORO A, Angelico G, Inzani F, Arciuolo D, et al The emerging and challenging role of PD-L1 in patients with gynecological
cancers: An updating review with clinico-pathological considerations.
Gynecol Oncol. 2024;184:57-66. PubMedAbstract available
TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Gynecol Oncol. 2024;184:74-82. PubMedAbstract available
WEHN AK, Qiu P, Lunceford J, Yarunin A, et al Concordance between an FDA-approved companion diagnostic and an alternative assay
kit for assessing homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2024;184:67-73. PubMedAbstract available
MOFFAT GT, Kong W, MacKay HJ, McGee J, et al Real-world outcomes associated with bevacizumab combined with chemotherapy in
platinum-resistant ovarian Cancer.
Gynecol Oncol. 2024;184:51-56. PubMedAbstract available
MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A
multicenter experience of the MITO group.
Gynecol Oncol. 2024;184:24-30. PubMedAbstract available
WINKLER SS, Tian C, Casablanca Y, Bateman NW, et al Racial, ethnic and country of origin disparities in aggressive endometrial cancer
histologic subtypes.
Gynecol Oncol. 2024;184:31-42. PubMedAbstract available
BAN D, Housley SN, Matyunina LV, McDonald LD, et al A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024;182:168-175. PubMedAbstract available
YANG Q, Peng X, Nian Z, Yuan S, et al UCHL-3 as a potential biomarker of ovarian cancer.
Gynecol Oncol. 2024;182:156-167. PubMedAbstract available
WEIGERT M, Cui XL, West-Szymanski D, Yu X, et al 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in
high-grade serous ovarian cancer.
Gynecol Oncol. 2024;182:82-90. PubMedAbstract available
TORTORELLA L, Cappuccio S, Giannarelli D, Nero C, et al Distribution and prognostic role of BRCA status in elderly ovarian cancer
patients.
Gynecol Oncol. 2024;182:57-62. PubMedAbstract available
LEVINE MD, Wang H, Sriram B, Khan A, et al Does the choice of platinum doublet matter? A study to evaluate the impact of
platinum doublet choice for treatment of platinum-sensitive ovarian cancer
recurrence on the development of future PARP inhibitor and platinum resistance.
Gynecol Oncol. 2024;182:51-56. PubMedAbstract available
KAHN RM, Ma X, Gordhandas S, Yeoshoua E, et al Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact
on patient travel in New York State.
Gynecol Oncol. 2024;182:141-147. PubMedAbstract available
CASANOVA J, Duarte GS, da Costa AG, Catarino A, et al Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid
endometrial cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2024;182:99-107. PubMedAbstract available
CRISTEA MC, Stewart D, Synold T, Ruel N, et al A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with
FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or
endometrial cancer, or triple negative breast cancer.
Gynecol Oncol. 2024;182:124-131. PubMedAbstract available
FIFE AJ, Najor AJ, Aspir TB, Haines KE, et al Reduced healthcare access contributes to delay of care in endometrial cancer.
Gynecol Oncol. 2024;182:115-120. PubMedAbstract available
KIM SI, Joung JG, Kim YN, Park J, et al Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated,
platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Gynecol Oncol. 2024;182:7-14. PubMedAbstract available
HANNIBAL CG, Kjaer SK, Galanakis M, Hertzum-Larsen R, et al History of autoimmune disease and long-term survival of epithelial ovarian
cancer: The extreme study.
Gynecol Oncol. 2024;182:1-6. PubMedAbstract available
GRESSEL GM, Frey MK, Norquist B, Senter L, et al Germline and somatic testing for ovarian Cancer: An SGO clinical practice
statement.
Gynecol Oncol. 2024;181:170-178. PubMedAbstract available
SZAMRETA EA, Monberg MJ, Desai KD, Li Y, et al Prognosis and conditional survival among women with newly diagnosed ovarian
cancer.
Gynecol Oncol. 2024;180:170-177. PubMedAbstract available
ALSOMAIRI A, Himayda S, Altelmesani A, Lee YJ, et al Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer:
Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence
in comparison to CA125.
Gynecol Oncol. 2024;181:155-161. PubMedAbstract available
December 2023
WU MF, Cheng XY, Wang DY, Lai YT, et al Determining the maximum tolerated dose of paclitaxel combined with fixed dose of
cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A
multicenter phase I trial.
Gynecol Oncol. 2023;181:125-132. PubMedAbstract available
PENVOSE KN, Reed SD, Sepulveda JMG, Mastylak A, et al Development and testing of patient-centered education about hormone replacement
therapy for women at high genetic risk of breast and ovarian cancer.
Gynecol Oncol. 2023;181:91-98. PubMedAbstract available
ALTMANN J, Schmitt W, Bashian N, Sehouli J, et al A dramatic response to checkpoint inhibitor in a woman with small cell carcinoma
of the hypercalcemic type of the ovary.
Gynecol Oncol. 2023;181:99-101. PubMedAbstract available
CHAN JK, Tian C, Kesterson JP, Lin KY, et al Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian
cancer - An NRG/GOG study.
Gynecol Oncol. 2023;181:54-59. PubMedAbstract available
KIM JH, Kim SI, Park EY, Kim ET, et al Comparison of survival outcomes between olaparib and niraparib maintenance
therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2023;181:33-39. PubMedAbstract available
BENOIT L, Boudebza A, Bentivegna E, Nguyen-Xuan HT, et al What is the most pertinent definition of malnutrition in epithelial ovarian
cancer to assess morbidity and mortality?
Gynecol Oncol. 2023;181:12-19. PubMedAbstract available
RICHARDSON MT, Barry D, Steinberg JR, Thirunavu V, et al Underrepresentation of racial and ethnic minority groups in gynecologic oncology:
An analysis of over 250 trials.
Gynecol Oncol. 2023;181:1-7. PubMedAbstract available
CHAUHAN S, Langstraat CL, Fought AJ, McGree ME, et al Relationship between frailty and nutrition: Refining predictors of mortality
after primary cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2023;180:126-131. PubMedAbstract available
YIN X, Zhao S, Zhang M, Xing J, et al m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in
epithelial ovarian cancer.
Gynecol Oncol. 2023;180:99-110. PubMedAbstract available
KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian
high-grade serous carcinoma.
Gynecol Oncol. 2023;180:91-98. PubMedAbstract available
CHASE DM, Annavarapu S, Tseng WY, Shi J, et al Health care services utilization in patients with ovarian cancer receiving PARP
inhibitor maintenance treatment in a US community oncology setting.
Gynecol Oncol. 2023;180:79-85. PubMedAbstract available
KAHN RM, Selenica P, Boerner T, Roche KL, et al Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in
ovarian cancer: Analysis of tumor phenotype and survival.
Gynecol Oncol. 2023;180:35-43. PubMedAbstract available
November 2023
NASIOUDIS D, Gysler S, Latif N, Cory L, et al Molecular landscape of ERBB2/HER2 gene amplification among patients with
gynecologic malignancies; clinical implications and future directions.
Gynecol Oncol. 2023;180:1-5. PubMedAbstract available
PRAISS AM, Hirani R, Zhou Q, Iasonos A, et al Impact of postoperative morbidity on outcomes in patients with advanced
epithelial ovarian cancer undergoing intestinal surgery at the time of primary or
interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team
Ovary study.
Gynecol Oncol. 2023;179:169-179. PubMedAbstract available
AGUSTI N, Vidal-Sicart S, Paredes P, Celada-Castro C, et al Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a
further step towards lymphadenectomy replacement.
Gynecol Oncol. 2023;179:145-151. PubMedAbstract available
DILLEY J, Gentry-Maharaj A, Ryan A, Burnell M, et al Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An
exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS).
Gynecol Oncol. 2023;179:123-130. PubMedAbstract available
LIM YH, Dagher C, Abu-Rustum NR, Mueller JJ, et al Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy
for the treatment of apparent early-stage endometrioid adenocarcinoma of the
uterus.
Gynecol Oncol. 2023;179:152-157. PubMedAbstract available
BAUMANN KE, Siamakpour-Reihani S, Dottino J, Dai Y, et al High-fat diet and obesity are associated with differential angiogenic gene
expression in epithelial ovarian cancer.
Gynecol Oncol. 2023;179:97-105. PubMedAbstract available
BESHAR I, Moon AS, Darji H, Liu C, et al Aberrant nuclear beta-catenin distribution does not prognosticate recurrences of
endometrioid endometrial cancers - A retrospective single-institutional study.
Gynecol Oncol. 2023;179:85-90. PubMedAbstract available
UCCELLA S, Bosco M, Mezzetto L, Garzon S, et al Major vessel resection for complete cytoreduction in primary advanced and
recurrent ovarian malignancies: A case series and systematic review of the
literature - pushing the boundaries in oncovascular surgery.
Gynecol Oncol. 2023;179:42-51. PubMedAbstract available
October 2023
KIM JH, Kim SI, Park EY, Ha HI, et al Impact of postoperative residual disease on survival in epithelial ovarian cancer
with consideration of recent frontline treatment advances: A systematic review
and meta-analysis.
Gynecol Oncol. 2023;179:24-32. PubMedAbstract available
RANDALL LM, O'Malley DM, Monk BJ, Coleman RL, et al Niraparib and dostarlimab for the treatment of recurrent platinum-resistant
ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol. 2023;178:161-169. PubMedAbstract available
LI S, Zhang X, Zhang T, Zhang R, et al Survival outcomes and establishment of a novel risk stratification system in
patients with ovarian yolk sac tumors.
Gynecol Oncol. 2023;178:145-152. PubMedAbstract available
BRZEZINSKA B, Mysona DP, Richardson KP, Rungruang B, et al High serum levels of inflammatory markers are associated with early recurrence in
patients with high-grade serous ovarian cancer after platinum therapy.
Gynecol Oncol. 2023;179:1-8. PubMedAbstract available
LEDERMANN JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian
cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol. 2023;178:119-129. PubMedAbstract available
IMTERAT M, Gebers G, Heitz F, Schneider S, et al Low anterior resection syndrome and its impact on quality of life of ovarian
carcinoma patients: A prospective longitudinal study.
Gynecol Oncol. 2023;178:96-101. PubMedAbstract available
MCLAUGHLIN HD, Greco P, Straubhar AM, Rolston A, et al Implementation of routine venous thromboembolism prophylaxis during neoadjuvant
chemotherapy for patients with ovarian cancer.
Gynecol Oncol. 2023;178:89-95. PubMedAbstract available
KOBEL M, Yang RZ, Kang EY, Al-Shamma Z, et al Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian
carcinomas.
Gynecol Oncol. 2023;178:80-88. PubMedAbstract available
NGUYEN NT, Raetz A, Montoya D, Schilling V, et al Targeting RAS-ERK pathway alterations with MEK inhibitors to improve
chemosensitivity in high grade serous ovarian cancers.
Gynecol Oncol. 2023;178:69-79. PubMedAbstract available
JORGENSEN K, Denham C, Kanbergs A, Wu CF, et al All-cause and cancer-specific mortality after fertility-sparing surgery for stage
IA and IC epithelial ovarian cancer.
Gynecol Oncol. 2023;178:60-68. PubMedAbstract available
September 2023
MARSH LA, Kim TH, Zhang M, Kubalanza K, et al Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its
association with outcome: A surrogate marker of survival.
Gynecol Oncol. 2023;177:173-179. PubMedAbstract available
WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al Pilot randomized trial of an acceptance-based telehealth intervention for women
with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol. 2023;177:165-172. PubMedAbstract available
DUUS AH, Zheng G, Baandrup L, Faber MT, et al Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on
histology and time since the procedure.
Gynecol Oncol. 2023;177:125-131. PubMedAbstract available
MOUFARRIJ S, Havrilesky L, Jewell EL Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
Gynecol Oncol. 2023;176:A1-A2. PubMed
MCGONIGAL S, Wu R, Grimley E, Turk EG, et al A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven
tumors.
Gynecol Oncol. 2023;176:139-146. PubMedAbstract available
LIU Y, Chen J, Lu Z, Chang X, et al Clinicopathological analysis of patients with molecularly confirmed stage I adult
granulosa cell tumors and prediction of recurrence.
Gynecol Oncol. 2023;176:106-114. PubMedAbstract available
August 2023
NARAYAN P, Ahsan MD, Webster EM, Perez L, et al Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A
systematic review and meta-analysis.
Gynecol Oncol. 2023;177:72-85. PubMedAbstract available
AO W, Kim HI, Tommarello D, Conrads KA, et al Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to
loss of CDC25A expression and resistance to ATRi treatment.
Gynecol Oncol. 2023;177:60-71. PubMedAbstract available
MARJON N, Guerra R, Freeman A, Mak J, et al Same day service: A genetic testing station model to improve germline genetic
testing in patients with ovarian cancer.
Gynecol Oncol. 2023;177:53-59. PubMedAbstract available
KIM JH, Park KN, Park EY, Jang MJ, et al Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on
postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized
trial.
Gynecol Oncol. 2023;177:32-37. PubMedAbstract available
HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are
clinicopathologically similar to pure clear cell carcinoma: An NRG
Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Gynecol Oncol. 2023;177:38-45. PubMedAbstract available
PIGNATA S, Bookman M, Sehouli J, Miller A, et al Overall survival and patient-reported outcome results from the placebo-controlled
randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for
newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol. 2023;177:20-31. PubMedAbstract available
TAYLOR DD, Gercel-Taylor C, Parker LP Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic
markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October
2009, Pages 112-120].
Gynecol Oncol. 2023;175:193. PubMed
TAYLOR DD, Gercel-Taylor C Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic
biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July
2008, Pages 13-21].
Gynecol Oncol. 2023;175:192. PubMed
July 2023
SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al Folate receptor alpha is widely expressed and a potential therapeutic target in
uterine and ovarian carcinosarcoma.
Gynecol Oncol. 2023;176:115-121. PubMedAbstract available
MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al Intra-racial disaggregation reveals associations between nativity and overall
survival in women with endometrial cancer.
Gynecol Oncol. 2023;176:98-105. PubMedAbstract available
HORVAT N, Causa Andrieu P, Meier A, Ji X, et al A preoperative nomogram incorporating CT to predict the probability of ovarian
clear cell carcinoma.
Gynecol Oncol. 2023;176:90-97. PubMedAbstract available
DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade
serous carcinoma.
Gynecol Oncol. 2023;176:76-81. PubMedAbstract available
SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al Leave it in the past - primary treatment modality for high-grade epithelial
ovarian cancer is not associated with secondary cytoreduction outcomes: A
Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2023;176:69-75. PubMedAbstract available
SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al Incidence of venous thromboembolism in patients with advanced stage ovarian
cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Gynecol Oncol. 2023;176:36-42. PubMedAbstract available
O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary,
fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology
group study 0283.
Gynecol Oncol. 2023;176:16-24. PubMedAbstract available
June 2023
TAYLOR KN, Li A, Manuel M, Rimel BJ, et al The association of black race with receipt of hysterectomy and survival in
low-risk endometrial cancer.
Gynecol Oncol. 2023;175:156-162. PubMedAbstract available
COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al Consensus statements and treatment algorithm to guide clinicians in the selection
of maintenance therapy for patients with newly diagnosed, advanced ovarian
carcinoma: Results of a Delphi study.
Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306. PubMedAbstract available
MORTON M, Haight PJ, Khadraoui W, Backes F, et al "More than a song and dance": Exploration of patient perspectives and educational
quality of gynecologic cancer content on TikTok.
Gynecol Oncol. 2023;175:81-87. PubMedAbstract available
SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer
in the United States.
Gynecol Oncol. 2023;175:60-65. PubMedAbstract available
POTHURI B, Blank SV, Myers TK, Hines JF, et al Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical
trials: A joint statement from GOG foundation and Society of Gynecologic Oncology
(SGO).
Gynecol Oncol. 2023;174:278-287. PubMed
SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al Disparities in clinical trial participation in ovarian cancer: A real-world
analysis.
Gynecol Oncol. 2023;175:25-31. PubMedAbstract available
BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al Corrigendum to "A RAD51 functional assay as a candidate test for homologous
recombination deficiency in ovarian cancer".
Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299. PubMed
May 2023
PEIPERT JD, Goble S, Isaacson J, Tang X, et al Patient-reported outcomes of maintenance rucaparib in patients with recurrent
ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol. 2023;175:1-7. PubMedAbstract available
EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53
mutated ovarian cancer: A biomarker-enriched phase II study.
Gynecol Oncol. 2023;174:239-246. PubMedAbstract available
PRAISS AM, Miller A, Smith J, Lichtman SM, et al Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group
study.
Gynecol Oncol. 2023;174:213-223. PubMedAbstract available
EURICH K, De La Cruz P, Laguna A, Woodman M, et al Multiplex serum immune profiling reveals circulating LAG-3 is associated with
improved patient survival in high grade serous ovarian cancer.
Gynecol Oncol. 2023;174:200-207. PubMedAbstract available
HANVIC B, Lecuru F, Vanacker H, Pautier P, et al Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the
multicentric Salome study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol. 2023;174:190-199. PubMedAbstract available
QIU Y, Zha J, Ma A, Zhou T, et al Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients
with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2023;174:175-181. PubMedAbstract available
FENG Z, Fu Y, Li R, Li H, et al Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of
epithelial ovarian cancer patients.
Gynecol Oncol. 2023;174:142-147. PubMedAbstract available
THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic
events associated with clinical outcome.
Gynecol Oncol. 2023;174:157-166. PubMedAbstract available
WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian
cancer: Tumor-First or Germline-First?
Gynecol Oncol. 2023;174:121-128. PubMedAbstract available
KIM SR, Madariaga A, Hogen L, Vicus D, et al Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
Gynecol Oncol. 2023;174:129-132. PubMedAbstract available
MOYETT JM, Howell EP, Broadwater G, Greene M, et al Understanding the spectrum of malignant bowel obstructions in gynecologic cancers
and the application of the Henry score.
Gynecol Oncol. 2023;174:114-120. PubMedAbstract available
NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al Tissue factor as a novel diagnostic target for early detection of ovarian cancer
using ultrasound microbubbles.
Gynecol Oncol. 2023;173:138-150. PubMedAbstract available
ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al Textbook outcome as a composite outcome measure to compare hospital performances
regarding cytoreductive surgery for ovarian cancer: A nationwide population-based
study.
Gynecol Oncol. 2023;174:89-97. PubMedAbstract available
SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol. 2023;174:34-41. PubMedAbstract available
SIA TY, Tew WP, Purdy C, Chi DS, et al The effect of older age on treatment outcomes in women with advanced ovarian
cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group
(GOG-0182-ICON5) ancillary study.
Gynecol Oncol. 2023;173:130-137. PubMedAbstract available
SAMUEL D, Kwon D, Huang M, Zhao W, et al Disparities in refusal of surgery for gynecologic cancer.
Gynecol Oncol. 2023;174:1-10. PubMedAbstract available
BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative
to improve patient receipt of cancer genetics services at five health systems.
Gynecol Oncol. 2023;172:106-114. PubMedAbstract available
April 2023
HANDLEY KF, Mehta S, Martin AL, Biswas S, et al Actionable spontaneous antibody responses antagonize malignant progression in
ovarian carcinoma.
Gynecol Oncol. 2023;173:114-121. PubMedAbstract available
PEREZ L, Webster E, Bull L, Brewer JT, et al Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for
ovarian cancer risk-reduction: A systematic review of the literature.
Gynecol Oncol. 2023;173:106-113. PubMedAbstract available
GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic
progression in relapsed ovarian cancer patients.
Gynecol Oncol. 2023;173:98-105. PubMedAbstract available
CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer
cell proliferation by activating the p53 signaling pathway.
Gynecol Oncol. 2023;173:31-40. PubMedAbstract available
PIGNATA S, Oza A, Hall G, Pardo B, et al Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer:
Outcomes by somatic and germline BRCA and other homologous recombination repair
gene mutation status in the ORZORA trial.
Gynecol Oncol. 2023;172:121-129. PubMedAbstract available
SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al Patterns of care and outcomes of risk reducing surgery in women with pathogenic
variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
Gynecol Oncol. 2023;173:1-7. PubMedAbstract available
HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al Ovarian preservation compared to oophorectomy in premenopausal women with
early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2023;173:8-14. PubMedAbstract available
March 2023
BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al HER2+ endometrioid endometrial cancer possesses distinct molecular and
immunologic features associated with a more active immune microenvironment and
worse prognosis.
Gynecol Oncol. 2023;172:98-105. PubMedAbstract available
AREND R, Dholakia J, Castro C, Matulonis U, et al DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2
basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol. 2023;172:82-91. PubMedAbstract available
MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the
MITO 22 trial.
Gynecol Oncol. 2023;172:72-77. PubMedAbstract available
OLULORO A, Temkin SM, Jackson J, Swisher EM, et al What's in it for me?: A value assessment of gynecologic cancer clinical trials
for Black women.
Gynecol Oncol. 2023;172:29-35. PubMedAbstract available
OSANN K, Wenzel L, McKinney C, Wagner L, et al Fear of recurrence, emotional well-being and quality of life among long-term
advanced ovarian cancer survivors.
Gynecol Oncol. 2023;171:151-158. PubMedAbstract available
BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al A RAD51 functional assay as a candidate test for homologous recombination
deficiency in ovarian cancer.
Gynecol Oncol. 2023;171:106-113. PubMedAbstract available
FOTOPOULOU C Intrathoracic surgery as part of primary cytoreduction for advanced ovarian
cancer: The evolution of a "pelvic" surgeon.
Gynecol Oncol. 2023;170:A1-A3. PubMed
LEE SS, Karpel HC, Oh C, Smith J, et al Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous
recombination repair pathway gene variant carriers.
Gynecol Oncol. 2023;170:234-240. PubMedAbstract available
LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al Predicting outcomes in female germ cell tumors using a modified International
Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol. 2023;170:93-101. PubMedAbstract available
February 2023
HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian
cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;171:83-94. PubMedAbstract available
JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al Minimally invasive interval debulking surgery for advanced ovarian cancer after
neoadjuvant chemotherapy.
Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017. PubMedAbstract available
January 2023
JAMIESON A, Singh N, Huvila J, Gilks CB, et al The continuing evolution of endometrial carcinoma molecular classification: Risk
stratification within the No Specific Molecular Profile (NSMP) subtype.
Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019. PubMed
HAN C, McNamara B, Bellone S, Harold J, et al The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor
neratinib are highly synergistic in HER2 overexpressing epithelial ovarian
carcinoma in vitro and in vivo.
Gynecol Oncol. 2023;170:172-178. PubMedAbstract available
MAURICIO D, Bellone S, Mutlu L, McNamara B, et al Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with
topoisomerase I inhibitor payload, shows antitumor activity in uterine and
ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol. 2023;170:38-45. PubMedAbstract available
September 2022
GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al Contemporary primary treatment of women with stage II-IV low-grade serous
ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free
survival.
Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591. PubMedAbstract available
RUSH SK, Lees BF, Huang DS, Peterson MF, et al Splenectomy at the time of primary or interval cytoreductive surgery for
epithelial ovarian carcinoma: A review of outcomes.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577. PubMedAbstract available
VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al The amount of preoperative endometrial tissue surface in relation to final
endometrial cancer classification.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570. PubMedAbstract available
August 2022
BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers
and potential to guide treatment in the adjuvant setting.
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551. PubMedAbstract available
MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al Patient self-reporting of tolerability using PRO-CTCAE in a randomized
double-blind, placebo-controlled phase II trial comparing gemcitabine in
combination with adavosertib or placebo in patients with platinum resistant or
refractory epithelial ovaria
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544. PubMedAbstract available